Friday, July 21, 2023 12:07:23 PM
Yes, the Sotorasib example has been used as an example of how fast the MHRA/NICE approves new drugs over in the UK.
And then we have the UK:
Sep 13, 2021 MHRA approves LUMYKRAS based on ORBIS (where UK has access to the FDA review so don't have to do the hard work themselves)
March,3 2022 Nice recommends LUMYKRAS
So despite ORBIS, MHRA was 4 months later than the FDA and actual use was almost a year later.
Yet, LPs paid pumpers keep asserting this is an example of how fast the MHRA/NICE are now.
Amgen PRs:
- TLD – 10.5.20
- BTD – 12.8.20
- FDA's RTOR Pilot Program submission – 12.8.20
- Sotorasib NDA submission to FDA – 12.16.20
- Sotorasib MAA submission to EMA – 12.22.20
- FDA's Project Orbis MAA submission to Australia, Brazil, Canada and the United Kingdom - Jan. 2021
- FDA Grants Sotorasib Priority Review Designation - 2.16.21
- FDA Approves LUMAKRAS™ (Sotorasib) -5.28.21
- EUROPEAN COMMISSION APPROVES LUMYKRAS® - 1.10.22....
And then we have the UK:
Sep 13, 2021 MHRA approves LUMYKRAS based on ORBIS (where UK has access to the FDA review so don't have to do the hard work themselves)
March,3 2022 Nice recommends LUMYKRAS
So despite ORBIS, MHRA was 4 months later than the FDA and actual use was almost a year later.
Yet, LPs paid pumpers keep asserting this is an example of how fast the MHRA/NICE are now.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
